Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2020 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
November 23, 2020 19:43 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in December Investor Conferences

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
November 10, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results

Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. ...
October 29, 2020 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in November Investor Conferences

AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
October 27, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020

AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
August 27, 2020 09:00 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company...
August 13, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports Second Quarter 2020 Results and Provides Update on Clinical and Corporate Activities

Lumos Pharma sells Priority Review Voucher (PRV), valued at $100 million - Lumos Pharma to receive $60 million for its 60% interest in PRVLumos Pharma reaffirms its expectation of the initiation of...
July 28, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma to Report Second Quarter 2020 Financial Results and Host a Conference Call on August 13, 2020

AUSTIN, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
July 27, 2020 16:05 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Announces Sale of Priority Review Voucher

AUSTIN, Texas, July 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that it has...
May 28, 2020 16:01 ET | Source: Lumos Pharma, Inc.

Lumos Pharma Reports First Quarter 2020 Results and Provides Update on Clinical and Corporate Activities

- Lumos Pharma expects to initiate its Phase 2b LUM-201 trial in Pediatric Growth Hormone Deficiency (PGHD) prior to the end of 2020 - Additional non-dilutive funds expected from anticipated...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right